Clinical trials: Psilocybin
Psilocybin Intoxication
The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of Psilocybin
This study will evaluate the subjective and behavioral effects of psilocybin relative to placebo and alcohol.
- Trial name
- NCT07877987
- Testing
- 0mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink, 1mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink, 5mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Psilocybin, Hallucinogens
Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators
This is a pilot study to finalize methods for a larger study being planned for the future. This research is being done to characterize performance of tasks, brain functioning, and the effects of psilocybin in individuals with a…
- Conditions
- Psilocybin, Hallucinogens, Pharmacologic Actions, Central Nervous System Agents
- Trial name
- NCT01988311
- Testing
- psilocybin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy
Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin
LSD (lysergic acid diethylamide) and psilocybin (the active substance in "magic mushrooms") are widely used for recreational purposes.
- Trial name
- LSD-psilo (NCT03604744)
- Testing
- LSD, Psilocybin
- Where
- Switzerland
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Psychedelic Effects in Healthy Volunteers
Psilocybin Administration With 5-HT1a Blockade
The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG).
- Trial name
- PsilBlock1 (NCT07565493)
- Testing
- Pindolol, Psilocybin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy
UW Psilocybin Pharmacokinetics Study
Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
- Trial name
- NCT02163707
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Psilocybin
The RECAP2 Study: Midazolam and Psilocybin
The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in…
- Trial name
- NCT06692192
- Testing
- Psilocybin, Midazolam, Saline
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Healthy
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
The acute subjective effects of serotonin (5-HT)2A receptor stimulation with psilocybin in humans are mostly positive. However, negative effects such as anxiety, paranoid thinking, or loss of trust towards other people are common…
- Trial name
- MDMA-Psilo (NCT06884514)
- Testing
- Psilocybin, 3,4-Methylenedioxymethamphetamine
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Psilocybin, Music Intervention
PRoMiSS: Psilocybin and the Role of Music in Set and Setting
The goal of this clinical trial is to understand how personally meaningful, autobiographically salient music compares to standardized playlists when combined with psilocybin in healthy adults ages 21 to 75.
- Trial name
- PRoMiSS (NCT07180108)
- Testing
- Psilocybin (high dose), Playlist 1, Playlist 2
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Mental Health
Mindfulness-Assisted Psychedelic Therapy
The goal of this clinical trial is to test psilocybin in combination with mindfulness training in healthy adults. The main question it aims to answer is "Does mindfulness training enhance the effects of psychedelic therapy…
- Trial name
- MAPT (NCT06233344)
- Testing
- Psilocybin plus mindfulness training, Psilocybin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Transdiagnostic, Depression - Major Depressive Disorder
Open-Label Psilocybin Study in Transdiagnostic Population
The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms.
- Conditions
- Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms
- Trial name
- NCT06442423
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University
Healthy Participants, Placebo - Control
The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.
In this study, participants will received either psilocybin (the active ingredient found in certain mushrooms) or an inactive placebo (a look-alike tablet with no active drug).
- Conditions
- Healthy Participants, Placebo - Control, Psilocybin
- Trial name
- PSILOBIOMARKER (NCT07433452)
- Testing
- Psilocybin (drug)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Gabriella Gobbi
Healthy
Comparative Acute Effects of LSD, Psilocybin and Mescaline
LSD, psilocybin and mescaline are widely used for recreational and ethnomedical purposes. All three substances are thought to induce prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor.
- Trial name
- LPM (NCT04227756)
- Testing
- LSD, Psilocybin, Mescaline
- Where
- Switzerland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Meditation, Microdosing
Optimizing Microdosing and Meditation
The goal of this clinical trial is to test the feasibility of combining meditation with psilocybin microdosing in healthy adults. The main questions it aims to answer are: 1. Recruitment and retention feasibility 2.
- Trial name
- OMM (NCT06560658)
- Testing
- Psilocybin, Meditation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National University of Natural Medicine
Aging
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
Participants in this study will undergo a series of non-invasive tests and activities designed to understand how a single dose of psilocybin might influence cognition and emotional well-being in healthy older adults.
- Trial name
- NCT06367738
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Healthy
Comparing the Effects of Psilocin and Psilocybin in Healthy Adults
To compare the physiological and psychological effects of psilocin taken orally by pill or sublingually by dissolving a tablet under the tongue to those of psilocybin taken by pill in healthy adults.
- Trial name
- NCT05317689
- Testing
- Psilocin, Psilocybin, Sublingual Psilocin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Personality
Personality and Drug Use (PDU)
The study aims to assess whether the use of drugs relates to personality ratings. Specifically, we plan to investigate if people with different histories of substance use differentiate on personality assessments (current and…
- Trial name
- PDU (NCT05180149)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Quantified Citizen Technologies Inc.
Basic Science
The Neurobiological Effect of 5-HT2AR Modulation
The investigators wish to investigate neurobiological effects of serotonin 2A receptor modulation in healthy volunteers, contrasting effects of an agonist (psilocybin) and an antagonist (ketanserin).
- Trial name
- NeuroPharm2 (NCT03289949)
- Testing
- Psilocybine, Ketanserin
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Gitte Moos Knudsen
Altered Waking States of Consciousness in Healthy Humans
Characterization of Altered Waking States of Consciousness in Healthy Humans
Altered waking states of consciousness and its underlying functional organization have gained increasing interest in recent years, i.e. in identifying the neural basis of consciousness.
- Trial name
- NCT03853577
- Testing
- TMS/EEG
- Where
- Switzerland
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Healthy Participants With Lower-than-average Mental Well-being
Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers
One hundred twenty healthy participants, ages 21 to 70, who experience moderate-to-lower-than-average mental well-being will be evenly randomized into four different study arms, using a 2x2 factorial design.
- Trial name
- SnS (NCT06626139)
- Testing
- Psilocybin, Context 1, Context 2
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Robin Carhart-Harris, PhD, MA
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants
MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is…
- Trial name
- NCT06643637
- Testing
- Psilocybin
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- MycoMedica Life Sciences PBC